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ABSTRACT
Background The global COVID-19 pandemic has had an 
unprecedented impact on European health and social care 
systems, with demands on testing, hospital and intensive 
care capacity exceeding available resources in many 
regions. This has led to concerns that some vulnerable 
groups, including autistic people, may be excluded from 
services.
Methods We reviewed policies from 15 European 
member states, published in March–July 2020, pertaining 
to (1) access to COVID-19 tests; (2) provisions for 
treatment, hospitalisation and intensive care units (ICUs); 
and (3) changes to standard health and social care. In 
parallel, we analysed survey data on the lived experiences 
of 1301 autistic people and caregivers.
Results Autistic people experienced significant barriers 
when accessing COVID-19 services. First, despite being at 
elevated risk of severe illness due to co- occurring health 
conditions, there was a lack of accessibility of COVID-19 
testing. Second, many COVID-19 outpatient and inpatient 
treatment services were reported to be inaccessible, 
predominantly resulting from individual differences in 
communication needs. Third, ICU triage protocols in many 
European countries (directly or indirectly) resulted in 
discriminatory exclusion from lifesaving treatments. Finally, 
interruptions to standard health and social care left over 
70% of autistic people without everyday support.
Conclusions The COVID-19 pandemic has further 
exacerbated existing healthcare inequalities for autistic 
people, probably contributing to disproportionate increases 
in morbidity and mortality, mental health and behavioural 
difficulties, and reduced quality of life. An urgent need 
exists for policies and guidelines on accessibility 
of COVID-19 services to be updated to prevent the 
widespread exclusion of autistic people from services, 
which represents a violation of international human rights 
law.
INTRODUCTION
Over 26 million SARS- CoV2 infections 
(hereafter COVID-19) and 550 000 COVID-
19- related deaths had been confirmed 
in Europe by the close of 2020, making it 
one of the worst hit regions worldwide.1 
During global viral pandemics and public 
health emergencies, like COVID-19, there 
is a significant risk that overwhelming and 
sustained demand for healthcare resources 
could exceed the capacity of health-
care systems.2 3 Consequently, mitigation 
measures to reduce pressure on health and 
social care systems have been implemented 
in many regions, including strict national 
lockdown policies (ie, restrictions on move-
ment) to slow virus transmission.4 Neverthe-
less, within just 1 month of COVID-19 being 
declared a global pandemic, the European 
Centre for Disease Prevention and Control 
reported that many EU countries were expe-
riencing unprecedented demands on testing 
capacity, personal protective equipment 
Strengths and limitations of this study
 ► Comprehensive review of regional and national pol-
icies and guidelines on access to COVID-19 health 
and social care services from 15 European countries.
 ► Large- scale survey of the lived experiences of 
1301 individuals from the autism community, cap-
turing real- world COVID-19 health and social care 
provision.
 ► Synthesis of policy and survey findings in the con-
text of a multi- disciplinary, participatory collabo-
ration, including autistic people, non- profit autism 
stakeholder organisations, clinical experts and re-
searchers from across Europe.
 ► Nuanced analysis and comparison of regional and 
national service provision is challenging due to vari-
ation in health and social care systems and a lack 
of available policy or survey data in some European 
countries.
 ► Self- selection of survey respondents and variation 
in the impact of COVID-19 across European coun-
tries might have introduced response or publication 
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(PPE), and hospital and intensive care capacity, far 
exceeding available resources.5 In such situations, 
disparities in healthcare access are magnified, leading 
to concerns that some groups of individuals, including 
autistic people, might be particularly vulnerable to 
being excluded from services, support and treatment in 
pandemic situations.6
Reports from the United States during the first global 
peak of COVID-19 infection indicated inequalities in 
access to COVID-19 services, with one study highlighting 
that 27 states had adopted ‘healthcare rationing’ policies 
that could harm autistic people and those with disabil-
ities (including intellectual disability).7 Furthermore, 
COVID-19 may disproportionately impact autistic people 
(who represent at least 1% of European citizens and 
at least 32% of whom have a co- occurring intellectual 
disability)8 9 due to elevated physical health comorbidi-
ties and existing healthcare inequalities. For example, 
physical health conditions are experienced at substan-
tially higher rates by autistic people compared with the 
general population, including conditions associated with 
high risk of severe illness from COVID-19 (eg, cardiovas-
cular or immune conditions, diabetes, obesity).10–12 In 
addition, autistic people experience numerous existing 
barriers to accessing general healthcare,13 which may 
also increase their risk of being excluded from COVID-19 
services. These barriers include communication or inter-
pretation difficulties, which can lead to misunderstand-
ings by healthcare providers and reduced involvement 
of patients in healthcare decision making (and might be 
exacerbated by mask wearing, which reduces the avail-
ability of non- verbal facial cues during interaction); diffi-
culties adjusting to change and novel procedures; sensory 
sensitivities (eg, around physical examinations, mask 
wearing); difficulties identifying or describing pains and 
symptoms; and inconsistent specialist clinician training, 
awareness and knowledge about autism and intellectual 
disability.13–15 Health providers might also misattribute 
COVID-19 symptoms to existing medical, mental health 
or behavioural problems, or autism itself (‘diagnostic 
overshadowing’), increasing the risk of severe disease due 
to missed or late diagnosis.16
Difficulties and delays in accessing COVID-19 services 
may partly explain why the UK death rate of people with 
intellectual disability (some of whom are also autistic) 
increased by 134% in the period from mid- April to May 
2019 compared with 2020, notably higher than in the 
total population, where deaths increased by 80%.17 18 
Additionally, at least 40–60% of confirmed deaths from 
COVID-19 across European countries with community 
transmission are believed to have occurred in long- term 
care facilities,19 a proportion of which offer residential 
care for autistic people. Of further concern, although 
guidelines around COVID-19 management and intellec-
tual disability were released by the World Health Orga-
nization in March 202020 and more detailed information 
has since been published by charities and clinical research 
teams,21–23 the extent to which these recommendations 
were distributed and implemented within national poli-
cies across Europe to safeguard autistic people is unclear.
We collated and reviewed regional or national poli-
cies and guidelines from 15 European member states, 
covering three priority areas: (1) access to COVID-19 
testing and screening; (2) provisions for treatment, hospi-
talisation and access to intensive care units (ICUs); and 
(3) access to standard health and social care. We consid-
ered whether current guidelines (directly or indirectly) 
discriminate against (or are protective of) autistic people. 
Furthermore, to capture lived experiences of COVID-19 
health and social care provision at the level of the indi-
vidual, Autism- Europe provided secondary data from a 
large- scale survey of autistic people and caregivers.
METHODS
Study design
AIMS-2- TRIALS is an international public–private part-
nership that brings together autistic people and their 
families, researchers and clinicians, charities, industry and 
pharmaceutical companies to improve understanding of 
autism and enhance treatment options for autistic people 
(https://www. aims- 2- trials. eu/). To assess COVID-19 
health and social care provision for autistic people, 
according to the priority areas described above, a two- 
step methodological approach was implemented. First, 
COVID-19 health and social care policies from 15 Euro-
pean countries were collated and reviewed by researchers, 
clinicians and non- profit groups from the AIMS-2- TRIALS 
Clinical Trials and Early Career Researchers in Autism 
Networks, and a panel of five representatives from the 
autism community.
Second, Autism- Europe provided de- identified 
secondary data from their large- scale survey of the impact 
of COVID-19 on 1301 autistic people and caregivers. An 
overview of the European countries represented in this 
review is presented in figure 1 and Autism- Europe respon-
dent characteristics in online supplemental table 1.
Materials and procedures
Review of European COVID-19 policy and guidelines
COVID-19- related policies and guidelines from 15 Euro-
pean countries (figure 1) were assessed using a common 
review template (please see online supplemental material 
1), indexing three priority areas: access to testing and 
screening; access to treatment, hospital and intensive 
care resources; and changes to existing health and social 
care. To be included, policies and guidelines had to be 
publicly available (ie, online/open access) and published 
between March and July 2020. A full list of included docu-
ments is provided in online supplemental table 2, with 
source of access specified.
Policies and guidelines were collated and translated 
into English by a panel of 30 AIMS-2- TRIALS early career 
autism researchers and five representatives from the 
autism community. In addition, documents were reviewed 
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by clinicians with extensive experience in autism diagnosis 
and intervention, who provided expert commentary.
Lived experiences from the autism community
As noted in the Introduction, where specific guidance has 
been published, the extent to which recommendations 
for supporting autistic people and those with intellectual 
disability have been implemented in everyday practice 
is unclear. Thus, alongside our policy review, Autism- 
Europe (an international, non- profit organisation: 
https://www. autismeurope. org/) also provided de- iden-
tified secondary data from their independent, large- scale 
survey of experiences of the COVID-19 pandemic from 
the autism community.
For the purposes of this review, we included Autism- 
Europe survey responses from the 15 countries for which 
we also had access to published policy or guidelines. We 
excluded respondents who were not autistic, or relatives/
caregivers (as the identity of ‘other’ respondents were 
not clearly defined), and those who opened but did not 
answer survey questions. This resulted in a final conve-
nience sample of 1301: 346 autistic people and 955 care-
givers. Please see online supplemental table 1 for survey 
demographics.
Survey items requested from Autism- Europe for the 
purpose of this review are documented in online supple-
mental table 3. The survey was disseminated publicly 
online between 7 April and 31 May 2020, in 10 languages, 
with participants recruited via Autism- Europe, UK autism 
charities and social media. Administration of the survey 
was conducted under the ‘Rights, Equality and Citizen-
ship programme 2014–2020’, funded by the European 
Commission. Respondents were notified of the Autism- 
Europe GDPR policy that responses would be used for 
the development of policy recommendations, and gave 
written permission for the publication of their anony-
mised quotations, which were included for illustrative 
purposes.
Public and patient involvement
Representatives from the autism community, and chari-
ties Autism- Europe and Autistica, were involved as active 
research partners in all aspects of the research through 
identifying priority areas for policy review, collating and 
reviewing policy guidelines in selected countries, inter-
preting findings, making recommendations for policy 
guidance, and editing or co- authoring the manuscript. 
Autism- Europe independently designed the survey 
content and collated all responses.
RESULTS
Review of European COVID-19 policy or guidelines (March–
July 2020)
Accessibility of COVID-19 testing and screening
First, we considered guidance on access to COVID-19 tests, 
particularly in the context of testing shortages. As explic-
itly acknowledged in documentation released by several 
European regions reviewed in this study—including the 
UK, the Netherlands and Belgium24–26—those with rele-
vant physical comorbidities and/or living in residential 
care meet criteria for priority COVID-19 testing. This 
guidance is relevant for autistic people, given a high 
proportion experience physical health comorbidities that 
are associated with increased risk of developing severe 
disease on contracting COVID-19, including cardiovas-
cular or respiratory illness, autoimmune conditions, 
diabetes, obesity and hypertension.
Second, approximately 5–25% of autistic people live 
in residential care (ie, higher intensity nursing or large 
group homes) and up to a further 27% in supported 
accommodation (ie, lower intensity congregate care 
settings in the community), with upper bound esti-
mates referring to those with co- occurring intellectual 
disability.27 This is notable because the transmission rate 
of COVID-19 in residential care settings is high due to 
factors such as care staff interacting with multiple resi-
dents throughout the day; global shortages of PPE and 
testing for care staff; difficulties for some individuals 
with strict adherence to personal hygiene practices; and 
impracticalities of maintaining physical distancing (eg, if 
residents require personal care).28 29
Despite existing evidence of increased risk of poor 
outcomes from COVID-19 for autistic people, our review 
indicated that they have not been routinely specified for 
priority access to testing across Europe. For instance, 
early in the COVID-19 pandemic, many regions with 
testing shortages initially prioritised essential workers 
and those hospitalised with suspected COVID-19 symp-
toms.30 In the UK and Ireland, care home residents 
(including those who were asymptomatic) were not offi-
cially added to the list for priority access to COVID-19 
testing until 29 and 17 April 2020, respectively, at least 
Figure 1 Schematic highlighting the 15 European countries 
included in this study, colour coded by number of Autism- 
Europe survey responses from each region: Spain, n=304; 
Italy, n=192; Greece, n=165; the Netherlands, n=143; 
Switzerland, n=144; France, n=86; United Kingdom, n=66; 
Germany, n=60; Malta, n=53; Belgium, n=34; Luxembourg, 
n=33; Austria, n=12; Ireland, n=5; Poland, n=3; Portugal, n=1.
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2 months after the first confirmed COVID-19 cases in 
these regions.26 31 Similarly, other countries that did not 
initially identify individuals in residential care settings 
as priority for testing, including the Netherlands and 
Belgium,24 25 now prioritise these groups; the Nether-
lands is the only country to directly prioritise individuals 
with serious behavioural problems in residential care for 
testing.
However, we did not identify any additional published 
guidance, or strategies specifically for enhancing accessi-
bility of testing for autistic people across any other country 
reviewed in this study. For instance, even in the countries 
identified above where individuals with certain physical 
comorbidities and those living in ‘high risk’ settings were 
prioritised for access to testing in case of shortages, there 
was no guidance published for those living in supported 
accommodation and the community. A lack of guidance 
was also identified for enhancing the tolerability (and 
thus accessibility) of test procedures for autistic people. 
For example, sensory sensitivities and difficulties around 
uncertainty and changes in routine are highly associated 
with autism,32 33 and COVID-19 diagnostic tests frequently 
involve nasal and throat swabs or aspiration,34 use of 
necessary PPE (a potential sensory and communication 
barrier), long waiting times and travel to an unfamiliar 
location—sometimes without the option to be accompa-
nied by a caregiver.
Access to treatment or hospitalisation
Next, we reviewed current recommendations for the treat-
ment and admission to hospital of autistic people who 
have COVID-19. Findings first highlighted that guidance 
from several European countries, including Belgium, Italy 
and the Netherlands, currently recommends that autistic 
people and those with behavioural problems are treated 
for COVID-19 within existing designated specialist neuro-
developmental or neuropsychiatric pathways, rather than 
general hospital settings.35 36
This approach may have some benefit in access to 
a greater range of specialist staff and resources to 
adequately support individuals with additional needs, 
as well as providing more flexibility around some regu-
lations (eg, allowing visitation by a caregiver or support 
person, with appropriate hygiene measures in place).
Nevertheless, in an open letter to EU leaders, the 
European Disability Forum specifically recommended 
that ‘persons with disabilities should not be segregated 
into separate facilities, where healthcare for COVID-19 
is often of a lower standard’.37 Examples of concerns 
about COVID-19 care provision in neurodevelopmental 
or psychiatric pathways include shortages of staff with 
medical or surgical and psychiatric expertise and expe-
rience. In addition, there are challenges for controlling 
infection spread in neurodevelopmental or psychiatric 
inpatient settings due to factors like close contact between 
patients and care providers and shortages of PPE, for 
which general hospitals may be prioritised.38
Access to intensive care
Our review indicated that—where officially docu-
mented—interpretation of ICU triage protocols and poli-
cies could pose a barrier to equitable care and access to 
lifesaving treatments (please see table 1).
For example, several European countries with 
published triage protocols recommend the consideration 
of ‘functional status’ and/or the use of ‘frailty assess-
ments’, including the UK, Ireland, France, the Nether-
lands, Italy, Belgium, Austria and Germany.39–47 These 
assessments were originally designed with reference to 
elderly populations to determine individuals with very 
poor prognosis for recovery from their current illness.48 
Despite this, concerns have been raised over ambiguity in 
some current guidance on the application and interpre-
tation of frailty assessments, whereby the support needs of 
some autistic people may be conflated with ‘frailty’.37 49 50 
As an example, frailty assessments refer to an individual’s 
dependency on others for support with daily care needs 
and personal care. Similarly, the assessment of functional 
status often includes quality of life outcomes, which are 
known to vary considerably among autistic people but 
may also be broadly underestimated because of a reliance 
on ‘neurotypical’ indicators of well- being.51
In light of these concerns—and in response to chal-
lenges by advocacy groups and a proposed judicial 
review52 53—on 25 March 2020, the UK National Institute 
for Health and Care Excellence amended their recom-
mendations to specify that frailty assessments should not 
be used for younger people or autistic people and those 
with intellectual disability.54 55 They also added weblinks 
to ethical guidance from medical associations (9 April 
2020) and stated that—where they are appropriate—
frailty assessments should be recorded in the patient’s 
medical record for transparency (29 April 2020). Similar 
clarifications on the lack of suitability of frailty assessment 
for those with intellectual disability have been published 
in the Netherlands.56 57 Nevertheless, such measures 
to prevent the misapplication of frailty assessments to 
autistic people have not been implemented systematically 
across European countries.
Moreover, the Working Group of Bioethics of the 
Spanish Society of Intensive, Critical Medicine and Coro-
nary Units published triage guidance that explicitly speci-
fies ‘severe baseline cognitive impairment’ as an exclusion 
criterion for ICU care.58 This recommendation is based 
on previous advice published in 2010 by the European 
Society of Intensive Care Medicine Task Force for ICU 
triage during an influenza epidemic, further specifying 
the exclusion of ‘a patient who is unable to perform activ-
ities of daily living due to cognitive impairment or is insti-
tutionalised due to cognitive impairment’.59 60 Similar 
guidance from the COVID-19 Paris region recommends 
attention to a patient’s previous condition, including 
neurocognitive status—mildly or severely impaired cogni-
tive functions.44
These criteria (and ambiguity in their intended appli-
cation to real- world clinical practice) plainly increase the 
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potential for discriminatory exclusion of autistic people, 
especially those with co- occurring intellectual disability, 
and are incompatible with international human rights 
laws (also emphasised by Spanish reports61 62); yet, they 
may be informing clinical decision making.63
Access to existing health and social care services
Overall, our review would suggest that the impact of 
COVID-19 has emphasised longstanding pressures on 
health and social care systems across Europe and pre- 
existing healthcare inequalities for autistic people. The 
first trend observed across all regions reviewed has been 
the abrupt interruption of usual social support and inter-
vention services to prevent infection spread. While an 
important safety precaution, without appropriate mitiga-
tion measures in place, for some individuals, services have 
ceased altogether.64
Usual health and social care services for autistic people 
have been particularly impacted in three key areas. First, 
many services were already stretched in non- pandemic 
times, including autism diagnostic services, for which 
average waiting times can be well over a year (a maximum 
of 13 weeks is recommended by the UK National Insti-
tute for Health and Care Excellence).65 Considered ‘non- 
essential’ in light of the COVID-19 pandemic, cancelled 
or postponed diagnostic appointments may further delay 
autistic people accessing needs- based support (eg, mental 
health interventions), which could be contingent on 
receiving a formal diagnosis.
Second, many community- based services across Europe 
(eg, day services, workshops, supported employment) are 
provided by the private sector and non- profit organisa-
tions. These organisations have reported experiencing 
acute financial instability due to COVID-1966 and are 
not always eligible to claim reimbursement for appoint-
ments that have been shifted to online delivery (though 
see flexible legislation from Belgium),67 meaning some 
have been forced to close completely.68 As a result, for 
some autistic people, relatives and other caregivers are 
currently the only available support people.
For those living in residential care settings, with low 
capacity for testing and PPE provisions, restrictions have 
been imposed on visitation from relatives or other care-
givers. These restrictions may include a complete ban on 
visitation, limits on the number of visitors and/or time 
limits on visitation.35 69–71 These measures are designed 
to prevent infection spread in ‘high risk’ long- term care 
facilities. However, loss of contact with relatives or care-
givers (also constituting a change in routine) could cause 
distress for autistic people and increase uncertainty and 
loneliness. Consequently, necessary restrictions on visi-
tation to residential care settings must be balanced with 
flexible options for alternative communication, such 
as regular and consistent access to video or telephone 
contact72—though it should be acknowledged that 
these options are not sufficient or appropriate for all 
individuals.
Finally, for those receiving community- based care, we 
also identified evidence from the UK of ‘easements’ to 
publicly funded adult social care in response to COVID-
19.73 These easements were introduced to relieve pressure 
on social care services and assist with prioritising support 
for those in highest need, by reducing the duty to carry 
out detailed assessments of individual care and support 
or financial needs, and reducing the duty to prepare or 
review individual care and support plans. We identified 
no published evidence to date that any local authorities 
in England have yet exercised social care easements.74 
Nevertheless, it is essential that this situation continues to 
be closely monitored to ensure that those in need receive 
adequate support, particularly given the significant lack 
of reliable data gathered on community- based health and 
social care provision across Europe.75
Lived experiences from the autism community (April–May 
2020)
Accessibility of COVID-19 testing and screening
Corresponding to findings from our policy review—
detailed above—the results from Autism- Europe’s survey 
of autistic people and caregivers (see table 2) also indi-
cated that despite being considered at increased risk of 
poor outcomes from COVID-19, there was a lack of acces-
sibility to COVID-19 testing.
For instance, 26% (n=327) of autistic people repre-
sented in Autism- Europe’s survey were reported to be 
considered at high risk from COVID-19. Nevertheless, 
of the 5% of autistic people who accessed a COVID-19 
test, 25% (n=13) felt they did not receive, or were unsure 
whether they had received, adequate accessible informa-
tion about the test procedure (table 2). Furthermore, 
only 39% (n=22) were provided with autism- specific 
reasonable adjustments (eg, allowed to be accompanied 
by a support person; tested in a quiet space). These issues 
were particularly emphasised by the report of one parent 
of a child with autism, who commented:
I wanted to get my son tested but there was no way 
to get this done without sedating him. This was not 
provided by the doctors and it was such a traumatic 
experience ended up [sic] not doing the test after 1.5 
hours of trying and quarantined instead for 2 weeks.
Access to treatment, hospitalisation and intensive care
Additionally, survey data showed that a proportion of 
autistic people also experienced difficulties accessing 
COVID-19 outpatient and inpatient treatment services.
Of the 2% (n=28) of autistic people captured by 
Autism- Europe’s survey who required COVID-19 treat-
ment, around half reported access difficulties (n=12), 
mostly accounted for by inaccessibility of the process 
of contacting healthcare providers (n=9; for example, 
contact by telephone was required):
Similarly, communication difficulties can represent a 
major barrier for receiving quality inpatient treatment 
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in general hospital settings, as noted by one person with 
autism:
I had to be hospitalised with acute abdominal cramps. 
On the spot, the nursing staff took my temperature 
and, worried, they did not know what to do: whether 
to put me in a separate room, because I could have 
COVID-19, or not. I was in the Emergency Room 
for 6 hours, the doctors deliberated my case, and in 
the end I was not tested. During the whole process, 
I was mute, paralysed. So I wonder if there is a way 
to communicate with the medical professionals about 
everyone’s situation without adding to the medical 
professionals' workload.
Moreover, concerns regarding inequalities in access to 
COVID-19 services could pose a barrier for seeking treat-
ment, with one autistic Autism- Europe survey respondent 
revealing:
I am also afraid that as a mentally impaired [sic] re-
cipient of a disability pension, during possible triage 
I will be rated worse than those capable of working of 
the same age (ableism) should there be shortages of 
medical care.
This comment highlights the importance of ensuring 
that public health information is made accessible for the 
autism community, with 65% (n=791) of Autism- Europe 
survey respondents being unaware or unsure of accessible 
information about current COVID-19 measures.
Access to existing health and social care services
Finally, reflecting the impact of the abrupt interrup-
tion of usual social support and intervention services on 
autistic people, 71% (n=595) of Autism- Europe survey 
respondents included in this review indicated that their 
usual support services had been stopped due to COVID-
19. This is notable given that approximately one third of 
those surveyed indicated that they required daily support 
(35%; n=451) and one third required occasional support 
with daily life activities (33%; n=431).
In addition, 33% (n=279) of Autism- Europe survey 
respondents stated that their usual support person was 
also at increased risk of COVID-19% and 63% (n=523) 
reported they did not have access to another support 
person if their usual caregiver became infected.
DISCUSSION
Summary of key findings and recommendations
We reviewed COVID-19 health and social care access for 
autistic people across 15 European member states, based 
on published policies or guidelines and results from a 
large- scale survey of over 1300 autistic people and care-
givers. Our findings highlighted several issues regarding 
Table 2 Autism- Europe survey responses for access to COVID-19 health and social care services for people with autism. 
Data are numbers (%)
Overall response Autistic person response Caregiver response
Yes No Unsure Yes No Unsure Yes No Unsure
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COVID-19 service access for autistic people that require 
rapid consideration, in terms of testing and screening; 
accessibility of treatment, hospitalisation and ICU care; 
and changes to standard health and social care provision.
Specifically, we identified (1) failure to prioritise and 
provide adequate adaptations to promote access to testing, 
despite elevated risk of severe COVID-19 disease due to 
commonly co- occurring physical health problems; (2) 
barriers for accessing treatment and hospitalisation (eg, 
alternative communication needs) and ICU triage proto-
cols that directly or indirectly (ie, through their ambi-
guity) discriminate against those with additional needs; 
and (3) abrupt interruptions to existing service provision 
(eg, mental health or community- based services) without 
appropriate mitigation measures, further exacerbated by 
longstanding pressures on health and social care. Consid-
ering these issues, we formulated a set of recommenda-
tions for policy and clinical practice to improve health 
and social care access for autistic people in pandemic 
situations and other public health emergencies (box 1).
Enhancing accessibility of COVID-19 testing and screening
As outlined above, our first key finding was a failure to 
prioritise and systematically provide adequate adapta-
tions to promote access to testing for autistic people. 
COVID-19 strategies published by the World Health 
Organization and European Commission emphasise 
the critical importance of testing people with suspected 
COVID-19 so that people with confirmed infection can 
be isolated and their close contacts traced.76 77 COVID-19 
testing strategies and capacity have varied among Euro-
pean countries. However, broadly, infrastructure limita-
tions (eg, manual processing of test data, financial) and 
supply shortages mean that testing capacity has fallen 
below growing demand across the EU.78 According to the 
World Health Organization and European Commission, 
in the case of insufficient testing capacity, priority groups 
for rapid testing in EU countries should include those 
at increased risk of developing severe disease (including 
acute respiratory illness and elderly populations with 
chronic health conditions); symptomatic health and 
social care workers; and those in closed settings, such as 
residential care homes76 79—criteria highly relevant to a 
proportion of autistic people.
However, it must be acknowledged that many autistic 
people experience additional barriers that could increase 
their risk of poor outcome from COVID-19, which should 
therefore also be explicitly acknowledged in policy and 
clinical documentation and guidance. These barriers 
include atypical symptom presentation (which may partly 
reflect high comorbidity burden and also lead to relevant 
comorbid physical health risk factors going undiagnosed), 
diagnostic overshadowing, and difficulties identifying 
and describing symptoms (see reviews of interoception 
difficulties and alexithymia in autism),80 81 which could 
lead to late or missed diagnosis, or misdiagnosis, and diffi-
culties gaining access to appropriate treatments.
Box 1 Recommendations for an aligned European 
strategy for reducing inequalities in access to health and 
social care services for autistic people and those with 
intellectual disability in pandemic situations
Policy recommendations
1. Policy documentation should explicitly outline strategies for promot-
ing equitable access to testing and screening for autistic people, 
including clinical guidance on identifying symptoms (given evidence 
for atypical symptom presentation, diagnostic overshadowing and 
high comorbidity burden), providing accessible inpatient and out-
patient care and enhancing the accessibility of testing procedures 
by providing preparatory materials and considering flexible test 
procedures (eg, saliva vs swab testing). Autistic people with phys-
ical health comorbidities and those living in ‘high risk’ settings for 
disease transmission, such as residential care and supported ac-
commodation, should be considered for priority access to proactive 
testing and screening, even when apparently asymptomatic.
2. If hospital admission is necessary, autistic people should receive 
the necessary accommodations and support to facilitate access to 
the same resources and standard of care as other individuals. This 
support may include the development of consistent policies to en-
sure: accessible information and communication methods; frequent 
consultation between the individual, their families (if appropriate) 
and care provider(s); formal guidance and training to support care 
providers from all specialities; greater flexibility in care provision.
3. Triage protocols across Europe require urgent review and update, 
in consultation with stakeholders (eg, intensive care and autism 
communities), to inform an aligned European strategy on the fair 
allocation of resources in public health emergencies that does not 
explicitly or inadvertently discriminate against any individual or 
groups of individuals on the grounds of pre- existing characteristics 
or difficulties.
4. The impact of COVID-19 on health and social care service provi-
sion should be comprehensively reviewed to inform mitigation or 
contingency plans for the safe and effective delivery of services in 
the short and longer term. In particular, the collection of high quality 
and reliable data on health and social care provision will support a 
targeted approach for identifying (cost- )effective strategies for re-
structuring and investment in health and social care, likely including 
greater flexibility in service provision (eg, telehealth, needs vs diag-
nosis based support) and community based care.
Clinical practice recommendations
1. Mandatory provision of alternative, accessible and easy- read 
healthcare information and communication toolkits.111 112
2. Mandatory consultation with autistic people to provide prior infor-
mation about themselves, their preferences and healthcare needs, 
in case they become unable to communicate on admission to hos-
pital (eg, the COVID-19 ‘Grab and Go’ Guide).113 This is essential 
to prevent healthcare decisions being made without the consent of 
patients and their families, as exemplified by the concerning ap-
plication of COVID-19 'Do not attempt resuscitation’ orders to the 
notes of some autistic people, without consultation.114
3. Mandatory, regularly updated formal guidelines and training for all 
healthcare providers, co- developed with autistic people and sup-
ported by access to specialist providers like learning disability or 
psychiatric liaison staff.35 63 115
4. Introducing flexibility to some regulations (if appropriate), such as 
allowing a caregiver or support person to accompany the individual 
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Considering these issues, our first recommendation 
for an aligned European strategy for responding to 
pandemic situations is that— in the case of testing short-
ages—autistic people should be considered for priority 
access to testing if they are living in ‘high risk’ settings for 
disease transmission (even when apparently asymptom-
atic), such as residential care and supported accommo-
dation (box 1).
To further promote equitable access to testing, it is 
important to also consider flexible testing methods to 
remove barriers for autistic people, who often experi-
ence sensory sensitivities associated with procedures like 
swab tests. Currently, if an individual is symptomatic but 
cannot be tested then good public health practice would 
be to treat the individual as a suspected case, which 
could result in enhanced (and potentially unnecessary) 
restrictions being disproportionately imposed on some 
groups of individuals with additional needs. Examples of 
methods for enhancing the accessibility of testing proce-
dures include the provision of high- quality preparatory 
materials, such as social stories and videos, available in 
different languages and easy- read formats, to demonstrate 
the testing procedure in advance (for examples, please 
see AsIAm 87). Moreover, for those who cannot tolerate 
swab testing, the use of non- invasive saliva sampling could 
be considered and can be readily performed at home. Of 
note, the utility of the saliva method for COVID-19 testing 
has been demonstrated82 83 and is already approved by the 
US Food and Drug Administration, and in use in some 
European countries, including Germany.
Enhancing access to treatment, hospitalisation and intensive 
care
Enhancing the accessibility of COVID-19 testing, particu-
larly in cases of shortage, has added potential to reduce the 
proportion of autistic people who require any treatment, 
hospitalisation or intensive care by reducing viral trans-
mission. This is significant given that autistic people often 
have suboptimal experiences of accessing healthcare and 
hospital admission,13–15 and experience higher odds of 
death in hospital. Furthermore, the resources required to 
adequately support autistic people during hospitalisation 
are likely to be considerably stretched in pandemic situ-
ations.84 There have been (and are currently) concerns 
across Europe about the ‘surge’ capacity of healthcare 
systems to cope with acute increases in patients requiring 
hospital and intensive care beds.85
Increasing capacity and investing in resilience plan-
ning should be the primary response for ensuring equal 
access to hospital and intensive care resources, across 
the population. Nevertheless, it is necessary for formal 
guidance to be provided for clinicians on the fair allo-
cation of resources in times of scarcity. For example, 
officially documented intensive care triage protocols for 
public health emergencies, combined with designated 
local ethics panels within healthcare settings, are essential 
to ensure that individual clinicians are never responsible 
for taking or implementing triage decisions and to avoid 
conflicts of interest.86 87 On the grounds of fundamental 
human rights, it is paramount that this guidance does not 
discriminate against individuals or groups of individuals 
on any illegitimate grounds, including developmental 
difference or disability, as highlighted in a recent open 
letter by the International Disability Alliance88–90 and 
reflected in the ICU triage protocols of eight of the 14 
European regions reviewed (please see table 1).
Consequently, our second set of recommendations 
relate to proper resourcing and care planning, which 
must be implemented to support autistic people who 
develop severe COVID-19 symptoms in general hospital 
settings (box 1).
While these recommendations have been specifically 
applied to supporting the needs of autistic people, it 
should be emphasised that they may be more broadly 
beneficial for other groups. For instance, introducing 
flexibility to regulations may also support individuals with 
intellectual disability (but not autism), other neurodevel-
opmental conditions (eg, attention deficit hyperactivity 
disorder and behavioural problems) and mental health 
conditions, such as anxiety. Similarly, the provision of 
accessible healthcare information and communication 
toolkits would be equally applicable for individuals with 
sight or hearing loss, or speech and language difficulties.91
Moreover, our third recommendation is that triage 
protocols are urgently reviewed and updated, in consul-
tation with stakeholders, to inform an aligned European 
strategy on the fair allocation of resources in public health 
emergencies (box 1). This strategy is essential to prevent 
the widespread exclusion of autistic people from ICU, to 
promote better healthcare equality across Europe, and to 
provide official guidance and support to regions where it 
is currently unavailable. Joint consultation between ICU 
clinicians and the autism community could further aid 
this progress by clarifying the application of triage proto-
cols in everyday clinical practice, reducing the potential 
for bias to enter into clinical and legislative recommenda-
tions, and promoting transparency to ensure that individ-
uals are not deterred from seeking services due to fear of 
exclusion.
Enhancing access to existing health and social care services
With the proper resourcing and funding of health and 
social care systems, the prospective need to implement 
triage protocols is reduced. After the economic crisis of 
2008–13, public spending on health slowed or fell across 
at least 24 European countries, both in absolute terms 
and as a share of overall government spending.92 In 
addition, there is very little available evidence to suggest 
Box 1 Continued
(already in place in regions of the UK, Germany and the Netherlands, 
according to clinician reviews) and making reasonable adjustments 
to ensure this flexibility is fulfilled in real- world clinical settings.
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the most (cost- )effective ways to provide social care for 
autistic people.93
Despite these issues, many non- emergency health and 
social care services have not altogether ceased as a result of 
COVID-19, but instead have been shifted from in- person 
to remote or online delivery (ie, ‘telehealth’). The fast 
implementation of telehealth in response to COVID-19 
could have a positive impact on clinical practice in the 
longer term,94 95 particularly for improving accessibility 
and reducing costs of health and social care services. 
For instance, one previous systematic review showed that 
outcomes of telehealth assessment and interventions for 
autistic people were broadly comparable to face- to- face 
consultations and superior to comparison groups who 
received no consultation at all.96 Additionally, telehealth 
may be particularly beneficial for enabling individuals 
who live in areas with particular service or specialist staff 
shortages to access high- quality support from elsewhere.97 
Thus, even prior to COVID-19, telehealth had been iden-
tified as a key area for promoting more effective, acces-
sible and resilient European healthcare systems.98
However, there is a lack of research about the most 
effective and appropriate methods for implementing tele-
health services that ensure continuity of care, and more 
data are needed about which in- person services (particu-
larly in the social care domain) are (or are not) conducive 
for remote implementation. Therefore, to ensure that 
telehealth fulfils its future positive potential to improve 
the quality of healthcare for autistic people and those with 
intellectual disability, more research is required on how 
it can be implemented in an accessible and personalised 
way.99 100 For instance, the European Disability Forum 
recommends that all information is provided in plain, 
easy- to- read language, alternative methods are provided 
for those who communicate by different means or who 
do not have access to certain technologies (eg, video, tele-
phone, email/messaging services), and the accessibility 
needs of different groups (including younger children) 
are considered—for example, appropriate sign language 
interpretation or captioning and symbols.101 Some of 
these recommendations require that the care provider 
has specialist training on supporting autistic people and 
those with intellectual disability, and all require future 
research into their efficacy in everyday clinical practice.
Overall and based on the evidence reported above, our 
final (and broadest) recommendation is that the impact 
of COVID-19 on health and social care service provision 
for autistic people is comprehensively reviewed to inform 
contingency plans for the safe and effective delivery of 
services in the short and longer term (box 1). This could 
include a shift to more community- based care and incor-
porating greater flexibility to ensure that services can 
quickly adapt to changing circumstances—for example, 
reducing the demand for a formal diagnosis of autism as 
a prerequisite for accessing needs- based support. Further-
more, there is a significant need for high- quality and reli-
able data75 to identify key areas for targeted restructuring 
and investment for improving health and social care 
provisions (eg, strategies for earlier detection of support 
needs and early interventions) for autistic people.
Learning from best practice and future directions
Though it is of paramount importance to address the 
barriers for COVID-19 health and social care services 
highlighted in this review, it should be noted that we 
also identified good examples of strategies to support 
autistic people and those with intellectual disability. Many 
services and individual professionals have made consid-
erable efforts to continue to support autistic people in 
these unprecedented times and shown incredible adapt-
ability and innovation. For instance, non- profit organisa-
tions across Europe have provided comprehensive and 
accessible online toolkits to support families and regular 
expert webinars on topics like mental health and coping 
with uncertainty.23 102 103 Additionally, some healthcare 
providers have implemented 24/7 telehealth services and 
live- in residential care.63 Several reasonable adjustments 
have also been made across Europe for autistic people, 
including exceptions on wearing face masks in public 
and allowing increased daily exercise during lockdown 
periods. Finally, in response to lobbying by non- profit 
organisations, new and amended guidance on supporting 
autistic people has started to be released, which we aim to 
complement and accelerate with the current report.
It is clear there are many additional issues facing autistic 
people in relation to COVID-19, which were beyond the 
scope of the current review, but must be investigated 
in future research. These issues include the impact of 
isolation; changes in education and employment; public 
understanding of adjustments to regulations for autistic 
people; and, now, how earlier policies have impacted on 
the accessibility of vaccination programmes and strate-
gies. In particular, the mental and physical health impacts 
of COVID-19 should be assessed, given high reported 
rates of pandemic- related stressors among families with 
a child with autism,104–106 and possible long- term mental 
and physical health implications of COVID-19 infec-
tion.107 108 Furthermore, longitudinal data on health and 
social care access and the impact of disruptions to educa-
tion and community facilities before, during and after 
the COVID-19 pandemic may reveal critical areas for 
addressing future policy and practice.
Strengths and limitations
This review represents the first comprehensive analysis 
of COVID-19 health and social care access for autistic 
people across 15 European countries, also capturing the 
lived experiences of over 1300 individuals from the autism 
community. Nevertheless, our findings must be consid-
ered in the context of the following limitations. First, it 
was not possible to collect information from all Euro-
pean countries in this study and there were important 
regional differences within countries that were included, 
in terms of COVID-19 policies and public health strat-
egies. As a result, the reported findings represent an 
overview, rather than a nuanced analysis, of the current 
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situation and approaches of each country. This limitation 
was somewhat unavoidable, given the constantly evolving 
situation, in which new sources and data were iteratively 
published and amended between March and July 2020. 
Moreover, European countries worst hit by the COVID-19 
pandemic (eg, the UK, Spain, Italy) had the most avail-
able resources and data, thus making them more eligible 
for inclusion. Despite this, evidence collated from coun-
tries where resources and data were freely accessible, 
combined with lived experiences from the autism commu-
nity through survey data, were paramount for informing 
our recommendations for an aligned European strategy 
for responding to pandemic situations.
Second, with the exception of triage protocols, we were 
largely unable to make direct comparisons between coun-
tries because each country has different health and social 
care systems. For instance, some health systems are free 
to the user, whereas in others a large proportion of the 
population have private health insurance.109 110 Similarly, 
the proportion of social care services provided by the 
government, non- profit and private organisations varies 
across Europe.110 To capture COVID-19 health and social 
care access, systematically adjusted for health system vari-
ability, it would be necessary to gather long- term data (eg, 
insurance data) before, during and after the COVID-19 
pandemic. However, in this study our primary aim was to 
collate current policies and guidelines to inform rapid 
recommendations for improving COVID-19 service access 
for autistic people prior to potential future peaks of the 
virus.
Finally, as with the policy review, response rates from 
the Autism- Europe survey were somewhat biased toward 
those countries particularly impacted by COVID-19, such 
as Italy and Spain. Response biases may also have been 
introduced by the convenience sampling method, the 
snapshot of time within which the survey was adminis-
tered and the informant—with the majority of included 
respondents (~73%) being caregivers, who may therefore 
be more likely to report on behalf of autistic people with 
particularly high support needs, including children and 
those with co- occurring intellectual disability (although 
it was not possible to confirm this on the basis of the 
available data). Despite this limitation, the inclusion of 
data on the lived experiences from the autism commu-
nity was crucial to demonstrate how policy and guidelines 
were being reflected in real- world practice and to ensure 
these experiences were reflected in recommendations for 
enhancing accessibility of services for autistic people.
CONCLUSIONS
The global COVID-19 pandemic has had an unprec-
edented impact on European health and social care 
systems, with supply chains and services forced to adapt 
rapidly to increased demand. In this review, we identified 
several significant barriers in access to COVID-19 services 
for autistic people, despite their increased risk of severe 
illness and mortality due to factors such as frequently 
co- occurring physical health conditions, difficulties with 
symptom identification, and living in residential care. 
Barriers for accessing COVID-19 services included (1) a 
lack of accessibility to testing, including difficulties toler-
ating swab procedures; (2) lack of access to outpatient 
and inpatient treatment, largely due to differences in 
communication needs (eg, difficulty using telephone); 
(3) ICU triage protocols that may directly or indirectly 
exclude individuals from lifesaving treatment; and (4) 
abrupt interruptions to standard health and social care, 
including mental health interventions. Considering the 
evidence reported, we provide specific recommendations 
for an aligned European strategy to reduce health and 
social care inequalities in public health emergencies (box 
1), which require particularly urgent consideration to 
enhance the future care of autistic people both during 
and beyond the pandemic.
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Supplementary Table 1 
Autism-Europe survey demographics, collected between April 7th and May 31st 2020. 
 
N respondent autistic person N respondent caregiver Gender 
M:F:NBa Age range 0-18 Age range 19-40 Age range 41-64 Age range 65+ Age range 0-18 Age range 18-40 Age range 41-65 Age range 65+ 
Region 
Austria 0 4 1 0 5 1 1 0 7:4:0 
Belgium 1 9 9 0 3 4 8 0 11:21:0 
France 0 21 9 1 13 12 26 4 30:52:1 
Germany 1 25 12 1 3 8 9 1 12:45:1 
Greece 1 4 1 0 6 46 107 0 24:127:0 
Ireland 0 2 1 0 1 0 1 0 2:3:0 
Italy 4 4 6 0 12 30 122 14 64:122:1 
Luxembourg 0 11 3 0 3 1 12 3 14:17:0 
Malta 0 1 0 0 11 23 16 1 8:33:0 
Netherlands 7 45 46 1 4 10 30 0 34:103:2 
Poland 0 1 0 0 0 1 0 1 0:3:0 
Portugal 0 0 0 0 0 0 0 1 0:1:0 
Spain 1 10 2 0 27 61 192 11 94:200:1 
Switzerland 3 34 19 1 16 17 53 1 47:95:1 
United Kingdom 2 18 23 1 1 6 13 2 16:42:4 
Note: Age ranges and gender refer to the autistic person reporting, or being reported on by a caregiver. aM=Male; F=Female; NB=Non-binary/ third gender. 
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Supplementary Material 1 
Common review templates for COVID-19 health and social care policies/ guidelines, distributed to the: a) AIMS-2-TRIALS early career autism researchers and panel of 
representatives from the autism community and; b) AIMS-2-TRIALS Clinical Trials Network. 
a) 
Enter: Country/ Region 
Source Summary of evidence 
Full source reference (include 
date and weblink, where 
relevant) 
Access to COVID-19 
screening/ testing 
Hospitalisation/ intensive care Social care/ self-isolation 
Changes to usual healthcare 
practice 





Include publication date and, 
where relevant, the full weblink. 
Consider: test availability; test 
procedure (e.g. sensory); 
getting test results; any other 
issues. 
 
Consider: availability of 
hospital/ intensive care beds; 
triage/ resource allocation; 
inclusion/ exclusion criteria; 
provision and quality of care; 
resuscitation orders; discharge 
procedures; any other issues. 
Consider: provision of social/ 
residential/ community care; 
support for individuals who are 
self-isolating or shielding; any 
other issues. 
Consider: access to/ delivery of 
standard services (e.g. mental 
health, remote delivery). 





Professional commentary on 
changes to regional services/ 
official guidance on service  
access (for AIMS-2-TRIALS 
Clinical Trials Network). 
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Supplementary Table 2. 
List of published policies/ guidelines included in this study, with source of access documented. 
Publication Date Language Source of access 






Dutch https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_procedure_hospitals_NL.pdf  
Ethics committee for 
















Dutch https://www.socialsecurity.be/citizen/nl/static/infos/coronavirus/index.htm# https://www.socialsecurity.be/citizen/nl/static/infos/coronavirus/index.htm# 





FPS Public Health, 
Food Chain Safety 











Belgium Society of 
Emergency and 
Disaster Medicine 






Flemish Agency for 





Flemish Agency for 






















National Institute for 
Health and 
Disability Insurance 
N/A Dutch https://www.riziv.fgov.be/nl/covid19/Paginas/default.aspx 
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The Netherlands    





Dutch https://www.rijksoverheid.nl/onderwerpen/coronavirus-covid-19/zorg/geestelijke-gezondheidszorg-ggz  
https://www.rijksoverheid.nl/onderwerpen/coronavirus-covid-19/nieuws/2020/03/23/nieuwe-bezoekersregeling-gehandicaptenzorg-en-ggz 
National Institute for 


























United Kingdom    
UK Department of 













English https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/guidance/outbreakmanagementguidance/RCF guidance document.pdf 





National Institute of 





UK Department of 

























? Italian http://www.siaarti.it/SiteAssets/News/COVID19%20-%20documenti%20SIAARTI/SIAARTI%20-%20Covid-19%20-%20Clinical%20Ethics%20Reccomendations.pdf 
Germany    
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Ethics Working 
Group of the 






























   
Council of Europe N/A Various 
languages 
https://www.coe.int/en/web/bioethics/selected-resources-by-country/ 








Service providers for 
Persons with 
Disabilities 







Spain    
The Spanish Society 































https://www.gouvernement.fr/sites/default/files/contenu/piece-jointe/2020/03/ attestation-deplacement-falc.pdf   
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17/03/20
20 
Poland    
Organisation for the 












Polish https://www.pfron.org.pl/aktualnosci/szczegoly-aktualnosci/news/pomoc-pfron-dla-osob-niepelnosprawnych-w-zwiazku-z-epidemia-koronawirusa/   
 
Portugal    
The Portuguese 
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Supplementary Table 3 
Autism-Europe survey items included in this review.  
Autism-Europe survey items 
Are you considered to be within the group at higher risk for COVID-19? 
Were you tested for COVID-19? 
 
If yes: Did you receive adequate/ accessible information about getting tested for COVID-19?  
If yes: Were any reasonable adjustments provided for autism needs during testing for COVID-19? 
Did you have to get treated in relation to COVID-19?  
 
If yes: Did you experience difficulty to contact healthcare professionals/ first aid responders during the COVID-19 spread?  
If yes: Was it due to the inaccessibility of the process e.g. contact to be made by phone? 
Do you need support for daily activities? 
 
Have your usual support services been interrupted since the beginning of the COVID-19 spread?  
Are your support person(s) considered at higher risk for COVID-19? 
 
If your support person(s) get(s) infected, do you have another support person? 
Is there accessible information available for autistic people on the COVID-19 spread and the current measures in place where you live? 
If you would like to make any comment, use the field below – optional. 
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Autistic people across Europe have struggled to access COVID-19 services during
pandemic
Likely result: rises in associated deaths, ill health, and poor quality of life, warn authors
Autistic people across Europe have not only struggled to access standard health and care
services during the pandemic, but, crucially, also those for COVID-19, finds research published in
the online journal BMJ Open.
The likely consequences of this widening of existing health inequalities for this community, will
have been to increase associated deaths, ill health, behavioural issues and poor quality of life,
warn the authors.
Amid concerns that the pandemic had excluded some vulnerable groups from health and care
services, the researchers reviewed the regional and national policies and guidelines of 15
European Union countries on access to COVID-19 treatment for autistic people, published
between March and July 2020.
They looked specifically at autistic people’s access to COVID-19 testing; provisions for hospital
and intensive care treatment; and changes to standard health and social care services.
They also analysed survey data from Autism-Europe on the lived experiences of 1301 autistic
people and caregivers in the included countries: Spain; Italy; Greece; the Netherlands;
Switzerland; France; the UK; Germany; Malta; Belgium; Luxembourg; Austria; Ireland; Poland;
and Portugal.
The findings showed that autistic people experienced significant barriers when accessing
COVID-19 services.
Despite being at heightened risk of serious illness, if infected with coronavirus, because of
co-existing health conditions, autistic people weren’t prioritised for COVID-19 testing.
The authors point out that between 5% and 25% of autistic people live in residential care, with up
to a further 27% living in supported accommodation, where transmission rates were high in the
first wave of the pandemic.
Even in countries where those with underlying conditions and those living in ‘high risk’ settings
were prioritised for access to testing, there was no guidance for those living in supported
accommodation and the community.
Nor was there any guidance on enhancing the tolerability (and therefore accessibility) of test
procedures for autistic people, many of whom have sensory sensitivities around swabbing, for
example, and don’t cope well with changes to their routine, such as visiting unfamiliar test sites,
note the researchers.
Second, many COVID-19 outpatient and inpatient treatment services were extremely hard to
access, largely because of individual differences in communication needs--access to use phone
services, for example.
Third, intensive care unit triage protocols in many European countries directly or indirectly
excluded autistic people from life-saving treatments.
Many of these protocols require ‘frailty assessments’ which refer to an individual’s dependency
on others for assistance with daily care needs and personal care.
While the unsuitability of these assessments for autistic people was recognised in some
countries, including in the UK and the Netherlands, measures to prevent the misapplication of
frailty and cognitive function assessments haven’t been implemented systematically across
European countries, note the researchers.
Finally, abrupt interruptions to standard health and social care with no mitigating measures in
place left over 70% of autistic people without everyday support, the survey responses showed.
Around a third of those surveyed said they required daily support (35%; 451) and another third
said they required occasional support with routine activities of daily living (33%; 431).
Many services were already stretched before the pandemic, including autism diagnostic services,
for which average waiting times can be well over a year, while many community services for
autistic people were forced to close, say the authors.
In light of their findings, they make a raft of policy and clinical practice recommendations to
reduce health and social care inequalities for autistic people across Europe during public health
emergencies.
These “require particularly urgent consideration to enhance the future care of autistic people both
during and beyond the pandemic,” they conclude.
